Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Posted on September 6, 2024 by Vaseline

Houston, Texas and Tübingen, Germany, September 6, 2024 – Immatics NV (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that updated clinical data on its lead cell therapy candidate, ACTengine IMA203 targeting PRAME, will be presented on the 21st^st International Congress of the Society for Melanoma Research.

Oral presentation

Related Posts

Finish! Genius from the direction of the master is evident after 7 years since the first meal for home cinema – Kino News

Babylon Berlin – TV program ONE

Ermittlungen weigh false single-bearing Abfälle at K+S Von dpa-AFX